{
  "abstract": "Background Our aim was to investigate the role of switching from emtricitabine/tenofovir alafenamide (TAF) based regimen to a dolutegravir and lamivudine (DTG) vs BIC/FTC/TAF (TAF) on metabolic parameters.Material and Methods Consecutive people living with HIV infection (PWH) enrolled in a multicenter observational cohort (SCOLTA) project, on a stable FTC/TAF based regimen with a HIV-RNA<50 copies/ml were included. Changes from baseline (T0) to follow-up (T1, week 24 and T2, week 36) were analyzed.Results Five hundred and twenty PWH met the inclusion criteria, 408 (78.5%) were males, 298 (57.3%) were on a previous cobicistat including regimen (COBI-IR).At T0 main characteristics were (mean ± standard deviation [SD]): age 49.7 ± 11.9 years, weight 75.9 Kg ±13.9, body mass index (BMI) 25.7 ± 4.1 kg/m2, total cholesterol (TC) 192 ± 41 mg/dL, LDL-cholesterol (LDL-c) 114 ± 36 mg/dL, CD4+ cell count median value was 680 cell/μL (interquartile range [IQR] 498-908), triglycerides (TGL) 113 mg/dL (IQR 82-158). Median time of observation was 32 months (IQR 16-48).PWH switching to DTG differed significantly by TAF for: INSTI and NNRTI in previous regimen (65.9% vs 81.0% and 25.4% vs 5.3% respectively; p<0.001), risk factor for HIV infection (Intravenous Drug users 6.3% vs 18.3%, sexual 87.3% vs 66.5%, other/unknown 6.4% vs 15.2%, p<0.0001), HCV coinfection (7.9% vs 18.3%, p<0.0001), baseline CD4 (median 772 [IQR 585-978] and 656 [IQR 469-882] , p=0.0005), CDC stage C (10.3% vs 18.3%, p=0.001), years of Antiretroviral Therapy (median 6.9 [IQR 3.1-13.3] vs 8.6 [IQR 3.8-17.1], p=0.01) and previous COBI-IR (33.3% in 2DR vs 65.9% in TAF, p<0.0001). PWH with previous COBI-IR had higher levels of TC (210 ± 39 mg/dl vs 196 ± 41 mg/dL, p=0.046) at enrollment. PWH on statin therapy were 11.1% in DTG vs 18.0% in TAF group (p=0.07).In a multivariate model adjusted for initial value of the variable, previous regimen class (with or without cobicistat), CDC stage, statin use and HCV-coinfection, no significant differences were found between DTG and TAF group as regards weight, BMI and lipid profile (see table 1).On the entire sample, TC reduced significantly in DTG group at T1 (-9 mg/dl [95% confidence interval -18 to -1], whereas at T2 the levels were still lower than T0 but not statistically significant. At T2 LDL-Cholesterol (LDL-c) showed a further decrease, both in DTG and TAF (-12 mg/dl [95% CI -23 to-2] and -9 mg/dl [95% CI -17 to -0] respectively) with no differences between the two groups.In PWH on previous COBI-IR we observed significant declines in TC and LDL-C both at T1 and T2 with no differences between DTG and TAF.Conclusions In PWH already on TAF, stopping TAF does not have an impact on lipid profile and BMI. Switching to DTG+3TC or BIC/FTC/TAF is associated with TC and LDL reduction independently of previous regimen. Weight and BMI were not influenced by switching TAF or COBI.Abstract P164 Table 1Blood lipids change to 6- and 12-month follow-up visit (multivariate model)",
  "authors": [
    {
      "affiliations": [
        "Infectious Diseases Unit Fondazione IRCCS, San Gerardo dei Tintori-University of Milano-Bicocca, Monza, Italy"
      ],
      "name": "N Squillace"
    },
    {
      "affiliations": [
        "Infectious Diseases, San Martino Hospital Genoa, University of Genoa, Genoa, Italy"
      ],
      "name": "L Taramasso"
    },
    {
      "affiliations": [
        "Fondazione ASIA Onlus, Buccinasco (MI), Italy"
      ],
      "name": "E Ricci"
    },
    {
      "affiliations": [
        "Unit of Infectious Diseases, ASST della Valle Olona – Busto Arsizio (VA), Italy"
      ],
      "name": "B Menzaghi"
    },
    {
      "affiliations": [
        "Department of Medicine and Surgery, Clinic of Infectious Diseases, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy"
      ],
      "name": "A Gidari"
    },
    {
      "affiliations": [
        "Division I of Infectious and Tropical Diseases, ASL Città di Torino, Italy"
      ],
      "name": "G Orofino"
    },
    {
      "affiliations": [
        "Unit of Infectious Diseases, Garibaldi Hospital, Catania, Italy"
      ],
      "name": "B M Celesia"
    },
    {
      "affiliations": [
        "Infectious Diseases Unit, SS. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy"
      ],
      "name": "E Sarchi"
    },
    {
      "affiliations": [
        "Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, Italy"
      ],
      "name": "S Piconi"
    },
    {
      "affiliations": [
        "Infectious Diseases, G. Martino Hospital -University of Messina, Messina. Italy"
      ],
      "name": "G Pellicano’"
    },
    {
      "affiliations": [
        "Unit of Infectious Diseases, Department of Medicine, Surgery, and Pharmacy, University of Sassari, Sassari, Italy"
      ],
      "name": "G Madeddu"
    },
    {
      "affiliations": [
        "Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy"
      ],
      "name": "S Ferrara"
    },
    {
      "affiliations": [
        "Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence, Italy"
      ],
      "name": "L Attala"
    },
    {
      "affiliations": [
        "Infectious Diseases, San Martino Hospital Genoa, University of Genoa, Genoa, Italy"
      ],
      "name": "A Di Biagio"
    },
    {
      "affiliations": [
        "Infectious Diseases Unit Fondazione IRCCS, San Gerardo dei Tintori-University of Milano-Bicocca, Monza, Italy"
      ],
      "name": "P Bonfanti"
    },
    {
      "affiliations": [
        "Infectious Diseases Unit Fondazione IRCCS, San Gerardo dei Tintori-University of Milano-Bicocca, Monza, Italy",
        "Infectious Diseases, San Martino Hospital Genoa, University of Genoa, Genoa, Italy",
        "Fondazione ASIA Onlus, Buccinasco (MI), Italy",
        "Unit of Infectious Diseases, ASST della Valle Olona – Busto Arsizio (VA), Italy",
        "Department of Medicine and Surgery, Clinic of Infectious Diseases, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy",
        "Division I of Infectious and Tropical Diseases, ASL Città di Torino, Italy",
        "Unit of Infectious Diseases, Garibaldi Hospital, Catania, Italy",
        "Infectious Diseases Unit, SS. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy",
        "Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, Italy",
        "Infectious Diseases, G. Martino Hospital -University of Messina, Messina. Italy",
        "Unit of Infectious Diseases, Department of Medicine, Surgery, and Pharmacy, University of Sassari, Sassari, Italy",
        "Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy",
        "Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence, Italy"
      ],
      "name": "for the CISAI Study Group"
    }
  ],
  "title": "P164 Switching to DTG/3TC or FTC/TAF/BIC in people living with HIV already on a stable TAF including regimen does not change weight and lipid profile",
  "uid": "5267efde-9888-5fd9-bff7-bec2c8107951"
}